<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00597558</url>
  </required_header>
  <id_info>
    <org_study_id>11-2299</org_study_id>
    <nct_id>NCT00597558</nct_id>
  </id_info>
  <brief_title>Treatment of Egg Allergy in Children Through Oral Desensitization (EGG OIT)</brief_title>
  <acronym>EggOIT</acronym>
  <official_title>Treatment of Egg Allergy in Children Through Oral Desensitization (EGG OIT)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of North Carolina, Chapel Hill</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Arkansas</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of North Carolina, Chapel Hill</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if children with egg allergy can be desensitized to
      egg protein and if this desensitization can help them outgrow their egg allergy at an earlier
      time than normal. Our hypothesis is that children with egg allergy can be orally desensitized
      to egg protein and that this desensitization will help them outgrow their egg allergy at an
      earlier time than normal.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Egg allergy in children under 5 years of age is extremely common. Egg, along with milk and
      peanuts, cause 80% of the food allergy reactions in children in the United States. Children
      have allergic reactions to egg ranging from mild urticaria to systemic anaphylaxis. The
      current therapy for children with egg allergy is to place the child on an egg-free diet until
      the allergy is outgrown. Because egg protein is a part of a significant number of processed
      foods it is difficult to totally avoid all egg proteins. Accidental ingestions leading to
      reactions to egg can occur with a bite of a cookie (~70 mg of egg protein) or a bite of a
      cake (~55 mg of egg protein). Children typically do not outgrow their egg allergy for several
      years. Therefore it would be helpful if a specific form of therapy would make children
      outgrow their allergic reactions to egg sooner. Egg protein is given to children in this
      study in small increasing amounts to desensitize them to the egg protein with the goal of
      helping them to outgrow their allergy.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2003</start_date>
  <completion_date type="Actual">August 2014</completion_date>
  <primary_completion_date type="Actual">August 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Double-blind, Placebo-controlled Food Challenge (DBPCFC) to Egg</measure>
    <time_frame>24-60 months</time_frame>
    <description>Subjects will have a double-blind, placebo-controlled food challenge (DBPCFC) to egg after at least 24 months of egg OIT when the IgE to egg is &lt; 7 kU/L or 90% of entry level IgE or SPT &lt;= 5mm with a maximum treatment period of 60 months.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Egg Protein Skin Prick Test After Egg OIT</measure>
    <time_frame>24-60 months</time_frame>
    <description>Wheal size on egg protein skin prick test at the end of egg OIT treatment compared with at baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum CAP-FEIA to Egg</measure>
    <time_frame>24-60 months</time_frame>
    <description>Measure of serum CAP-FEIA to egg from subjects on egg OIT after completion of treatment compared to baseline</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">13</enrollment>
  <condition>Food Hypersensitivity</condition>
  <arm_group>
    <arm_group_label>Egg white protein</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects, who are egg allergic, are given egg white protein for desensitization with the hypothesis they will develop tolerance.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Egg white protein</intervention_name>
    <description>Egg white protein powder</description>
    <arm_group_label>Egg white protein</arm_group_label>
    <other_name>Egg OIT</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Between 1 to 16 years of age

          -  Diagnosed egg allergy by CAP FEIA to egg of 5 kU/l or greater (2 kU/l or greater if 2
             years old or less) or have had a positive allergic reaction to egg within 6 months.

          -  Having eaten egg in his/her diet prior to diagnosis

          -  A family that will be able to be compliant with all study visits

          -  All females of child bearing age must be using appropriate birth control

        Exclusion Criteria:

          -  History of anaphylaxis to egg

          -  Medical history that would prevent a DBPCFC (double-blind placebo-controlled food
             challenge) to egg. The medical history that would prevent the DBPCFC to egg would be a
             prior history of an open egg challenge in which the patient experienced hypotension
             which required fluid resuscitation, respiratory compromise which necessitated
             ventilatory support, or poorly controlled asthma as evidenced by an FEV1 &lt; 80% of
             predicted, or FEV1/FVC &lt;75%, with or without controller medications

          -  Unable to cooperate with challenge procedures or unable to be reached by telephone for
             follow-up

          -  Diagnosed corn allergy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>16 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wesley Burks, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of North Carolina, Chapel Hill</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Arkansas</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UNC Chapel Hill</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Buchanan AD, Green TD, Jones SM, Scurlock AM, Christie L, Althage KA, Steele PH, Pons L, Helm RM, Lee LA, Burks AW. Egg oral immunotherapy in nonanaphylactic children with egg allergy. J Allergy Clin Immunol. 2007 Jan;119(1):199-205. Epub 2006 Oct 27.</citation>
    <PMID>17208602</PMID>
  </results_reference>
  <results_reference>
    <citation>Vickery BP, Pons L, Kulis M, Steele P, Jones SM, Burks AW. Individualized IgE-based dosing of egg oral immunotherapy and the development of tolerance. Ann Allergy Asthma Immunol. 2010 Dec;105(6):444-50. doi: 10.1016/j.anai.2010.09.030.</citation>
    <PMID>21130382</PMID>
  </results_reference>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 6, 2008</study_first_submitted>
  <study_first_submitted_qc>January 15, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 18, 2008</study_first_posted>
  <results_first_submitted>April 7, 2016</results_first_submitted>
  <results_first_submitted_qc>April 8, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 16, 2016</results_first_posted>
  <last_update_submitted>February 27, 2018</last_update_submitted>
  <last_update_submitted_qc>February 27, 2018</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 26, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Egg allergy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypersensitivity</mesh_term>
    <mesh_term>Food Hypersensitivity</mesh_term>
    <mesh_term>Egg Hypersensitivity</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Egg White Protein Powder</title>
          <description>Egg allergic subjects who ingest oral egg white protein for desensitization and possible tolerance.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Egg White Protein Powder</title>
          <description>Egg allergic subjects who ingest oral egg white protein for desensitization and possible tolerance.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="13"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6.6" lower_limit="3.6" upper_limit="13.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Double-blind, Placebo-controlled Food Challenge (DBPCFC) to Egg</title>
        <description>Subjects will have a double-blind, placebo-controlled food challenge (DBPCFC) to egg after at least 24 months of egg OIT when the IgE to egg is &lt; 7 kU/L or 90% of entry level IgE or SPT &lt;= 5mm with a maximum treatment period of 60 months.</description>
        <time_frame>24-60 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Egg White Protein Powder</title>
            <description>Egg allergic subjects who ingest oral egg white protein</description>
          </group>
        </group_list>
        <measure>
          <title>Double-blind, Placebo-controlled Food Challenge (DBPCFC) to Egg</title>
          <description>Subjects will have a double-blind, placebo-controlled food challenge (DBPCFC) to egg after at least 24 months of egg OIT when the IgE to egg is &lt; 7 kU/L or 90% of entry level IgE or SPT &lt;= 5mm with a maximum treatment period of 60 months.</description>
          <units>subjects with no symptoms on DBPCFC</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Egg Protein Skin Prick Test After Egg OIT</title>
        <description>Wheal size on egg protein skin prick test at the end of egg OIT treatment compared with at baseline.</description>
        <time_frame>24-60 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Egg White Protein Powder</title>
            <description>Egg allergic subjects who ingest oral egg white protein</description>
          </group>
        </group_list>
        <measure>
          <title>Egg Protein Skin Prick Test After Egg OIT</title>
          <description>Wheal size on egg protein skin prick test at the end of egg OIT treatment compared with at baseline.</description>
          <units>mm</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.8" lower_limit="0" upper_limit="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serum CAP-FEIA to Egg</title>
        <description>Measure of serum CAP-FEIA to egg from subjects on egg OIT after completion of treatment compared to baseline</description>
        <time_frame>24-60 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Egg White Protein Powder</title>
            <description>Egg allergic subjects who ingest oral egg white protein</description>
          </group>
        </group_list>
        <measure>
          <title>Serum CAP-FEIA to Egg</title>
          <description>Measure of serum CAP-FEIA to egg from subjects on egg OIT after completion of treatment compared to baseline</description>
          <units>ku/L</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.7" lower_limit="0.35" upper_limit="8.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>24-60 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Egg White Protein Powder</title>
          <description>Egg allergic subjects who ingest oral egg white protein</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Eye itch</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Eye tearing</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Sneezing</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Nasal itch</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Rhinorrhea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Oropharyngeal itch</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Wheezing</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Erythematous rash</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Skin itch</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Hives</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Lip or eye swelling</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Endpoints were based on reaching certain lab criteria and thus the time on treatment varied from 24-60 months.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Edwin Kim, Director</name_or_title>
      <organization>University of North Carolina at Chapel Hill</organization>
      <phone>919-843-9087</phone>
      <email>edwinkim@email.unc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

